Literature DB >> 26113601

Non-small cell lung cancer cell survival crucially depends on functional insulin receptors.

Carolin Maria Frisch1, Katrin Zimmermann1, Pia Zilleßen1, Alexander Pfeifer1, Kurt Racké1, Peter Mayer2.   

Abstract

Insulin plays an important role as a growth factor and its contribution to tumor proliferation is intensely discussed. It acts via the cognate insulin receptor (IR) but can also activate the IGF1 receptor (IGF1R). Apart from increasing proliferation, insulin might have additional effects in lung cancer. Therefore, we investigated insulin action and effects of IR knockdown (KD) in three (NCI-H292, NCI-H226 and NCI-H460) independent non-small cell lung cancer (NSCLC) cell lines. All lung cancer lines studied were found to express IR, albeit with marked differences in the ratio of the two variants IR-A and IR-B. Insulin activated the classical signaling pathway with IR autophosphorylation and Akt phosphorylation. Moreover, activation of MAPK was observed in H292 cells, accompanied by enhanced proliferation. Lentiviral shRNA IR KD caused strong decrease in survival of all three lines, indicating that the effects of insulin in lung cancer go beyond enhancing proliferation. Unspecific effects were ruled out by employing further shRNAs and different insulin-responsive cells (human pre-adipocytes) for comparison. Caspase assays demonstrated that IR KD strongly induced apoptosis in these lung cancer cells, providing the physiological basis of the rapid cell loss. In search for the underlying mechanism, we analyzed alterations in the gene expression profile in response to IR KD. A strong induction of certain cytokines (e.g. IL20 and tumour necrosis factor) became obvious and it turned out that these cytokines trigger apoptosis in the NSCLC cells tested. This indicates a novel role of IR in tumor cell survival via suppression of pro-apoptotic cytokines.
© 2015 Society for Endocrinology.

Entities:  

Keywords:  IGF receptor; apoptosis; carcinoma; insulin; insulin receptor

Mesh:

Substances:

Year:  2015        PMID: 26113601     DOI: 10.1530/ERC-14-0581

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  8 in total

1.  Carcinogenic effects of oil dispersants: A KEGG pathway-based RNA-seq study of human airway epithelial cells.

Authors:  Yao-Zhong Liu; Lei Zhang; Astrid M Roy-Engel; Shigeki Saito; Joseph A Lasky; Guangdi Wang; He Wang
Journal:  Gene       Date:  2016-11-16       Impact factor: 3.688

Review 2.  Insulin Receptor Isoforms in Physiology and Disease: An Updated View.

Authors:  Antonino Belfiore; Roberta Malaguarnera; Veronica Vella; Michael C Lawrence; Laura Sciacca; Francesco Frasca; Andrea Morrione; Riccardo Vigneri
Journal:  Endocr Rev       Date:  2017-10-01       Impact factor: 19.871

Review 3.  Obesity and cancer, a case for insulin signaling.

Authors:  Y Poloz; V Stambolic
Journal:  Cell Death Dis       Date:  2015-12-31       Impact factor: 8.469

4.  Comprehensive Pulmonary Safety Review of Inhaled Technosphere® Insulin in Patients with Diabetes Mellitus.

Authors:  Janet B McGill; Anne Peters; John B Buse; Susanne Steiner; Tiffany Tran; Frank M Pompilio; David M Kendall
Journal:  Clin Drug Investig       Date:  2020-10       Impact factor: 2.859

Review 5.  Obesity, Type 2 Diabetes, and Cancer Risk.

Authors:  Tiffany Scully; Abora Ettela; Derek LeRoith; Emily Jane Gallagher
Journal:  Front Oncol       Date:  2021-02-02       Impact factor: 6.244

Review 6.  Insulin-Lowering Diets in Metastatic Cancer.

Authors:  Sherry Shen; Neil M Iyengar
Journal:  Nutrients       Date:  2022-08-27       Impact factor: 6.706

Review 7.  Hypothalamic Mitochondrial Dysfunction as a Target in Obesity and Metabolic Disease.

Authors:  Juan Cunarro; Sabela Casado; Javier Lugilde; Sulay Tovar
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-31       Impact factor: 5.555

Review 8.  Insulin Receptor Isoforms in Cancer.

Authors:  Veronica Vella; Agostino Milluzzo; Nunzio Massimo Scalisi; Paolo Vigneri; Laura Sciacca
Journal:  Int J Mol Sci       Date:  2018-11-16       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.